Jéssica Guedes , Nicole Woldmar , A. Marcell Szasz , Elisabet Wieslander , Krysztof Pawłowski , Peter Horvatovich , Johan Malm , Leticia Szadai , István Balázs Németh , György Marko-Varga , Jeovanis Gil
{"title":"A perspective on integrating digital pathology, proteomics, clinical data and AI analytics in cancer research","authors":"Jéssica Guedes , Nicole Woldmar , A. Marcell Szasz , Elisabet Wieslander , Krysztof Pawłowski , Peter Horvatovich , Johan Malm , Leticia Szadai , István Balázs Németh , György Marko-Varga , Jeovanis Gil","doi":"10.1016/j.jprot.2025.105493","DOIUrl":null,"url":null,"abstract":"<div><div>Nearly 40 % of individuals will be diagnosed with cancer in their lifetime, translating to an estimated 20 million new cases annually. Despite remarkable therapeutic advances, only 15–20 % of patients achieve durable responses to immunotherapy, and the high cost of treatment (illustrated by immune checkpoint inhibitors like pembrolizumab and nivolumab, totaling roughly $191,000 per year) remains a formidable global challenge. The convergence of digital pathology, high-throughput molecular profiling, and advanced computational strategies has the potential to transform cancer research. By integrating high-resolution morphological data with proteomic, transcriptomic, and spatial molecular insights, we can elucidate the complex interplay between tumor cells and their microenvironment. In this perspective, we review how emerging techniques, from AI-driven image analysis to deep visual proteomics, can accelerate biomarker discovery, refine patient stratification, and ultimately improve clinical outcomes. We illustrate these principles with a case study in melanoma, where the integration of digital pathology and deep proteomic profiling uncovered a molecular signature predictive of recurrence in early-stage disease. As these technologies evolve, we foresee a future of precision oncology characterized by the seamless integration of morphological, clinical, and molecular data enabled by AI-driven analytics.</div></div><div><h3>Significance</h3><div>This perspective represents a pivotal step toward transforming cancer research by bridging the gap between traditional histopathological evaluation and modern molecular analytics. By integrating digital pathology with spatial proteomics and advanced AI-driven analytics, our approach provides a multidimensional view of tumor biology that captures both morphological nuances and molecular heterogeneity. This comprehensive framework not only enhances our understanding of the tumor microenvironment but also facilitates the discovery of robust biomarkers for disease recurrence and therapeutic response. Ultimately, our findings underscore the potential of precision oncology to tailor treatment strategies to individual patient profiles, thereby improving clinical outcomes and guiding the next generation of personalized cancer care.</div></div>","PeriodicalId":16891,"journal":{"name":"Journal of proteomics","volume":"320 ","pages":"Article 105493"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of proteomics","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1874391925001204","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Nearly 40 % of individuals will be diagnosed with cancer in their lifetime, translating to an estimated 20 million new cases annually. Despite remarkable therapeutic advances, only 15–20 % of patients achieve durable responses to immunotherapy, and the high cost of treatment (illustrated by immune checkpoint inhibitors like pembrolizumab and nivolumab, totaling roughly $191,000 per year) remains a formidable global challenge. The convergence of digital pathology, high-throughput molecular profiling, and advanced computational strategies has the potential to transform cancer research. By integrating high-resolution morphological data with proteomic, transcriptomic, and spatial molecular insights, we can elucidate the complex interplay between tumor cells and their microenvironment. In this perspective, we review how emerging techniques, from AI-driven image analysis to deep visual proteomics, can accelerate biomarker discovery, refine patient stratification, and ultimately improve clinical outcomes. We illustrate these principles with a case study in melanoma, where the integration of digital pathology and deep proteomic profiling uncovered a molecular signature predictive of recurrence in early-stage disease. As these technologies evolve, we foresee a future of precision oncology characterized by the seamless integration of morphological, clinical, and molecular data enabled by AI-driven analytics.
Significance
This perspective represents a pivotal step toward transforming cancer research by bridging the gap between traditional histopathological evaluation and modern molecular analytics. By integrating digital pathology with spatial proteomics and advanced AI-driven analytics, our approach provides a multidimensional view of tumor biology that captures both morphological nuances and molecular heterogeneity. This comprehensive framework not only enhances our understanding of the tumor microenvironment but also facilitates the discovery of robust biomarkers for disease recurrence and therapeutic response. Ultimately, our findings underscore the potential of precision oncology to tailor treatment strategies to individual patient profiles, thereby improving clinical outcomes and guiding the next generation of personalized cancer care.
期刊介绍:
Journal of Proteomics is aimed at protein scientists and analytical chemists in the field of proteomics, biomarker discovery, protein analytics, plant proteomics, microbial and animal proteomics, human studies, tissue imaging by mass spectrometry, non-conventional and non-model organism proteomics, and protein bioinformatics. The journal welcomes papers in new and upcoming areas such as metabolomics, genomics, systems biology, toxicogenomics, pharmacoproteomics.
Journal of Proteomics unifies both fundamental scientists and clinicians, and includes translational research. Suggestions for reviews, webinars and thematic issues are welcome.